Due to the functional complementarity and redundancy of MCT1 and MCT4, as well as metabolic symbiosis established based on the lactate shuttle, combined inhibition of MCT1 and MCT4 demonstrates the preclinical efficacy for osteosarcoma treatment. The gene discussed is SLC16A4; the disease is osteosarcoma.